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Summary 
Studies were initiated to localize the C-reactive protein (CRP) binding site on the coUagen-like 
region (CLR) of Clq. CRP bound preferentially to the A chain of reduced Clq, in contrast 
to aggregated immunoglobulin G (Agg-IgG), which reacted preferentially with the C chain. 
A group of Clq A chain peptides, including peptides identical to residues  81-97,  76-92,  and 
14-26, respectively, were synthesized from predicted binding regions. Peptide 76-92 contained 
two proximal lysine groups, and peptide 14-26 contained four proximal arginine groups. CRP- 
trimers and CRP-ligand complexes did not bind to immobilized peptide 81-97, but bound avidly 
to immobilized peptides 76-92 and 14-26. Agg-IgG did not bind to any of the peptides. Peptide 
76-92 partially,  and peptide 14-26 completely, inhibited binding of CRP to intact Clq. Peptide 
14-26 also blocked C consumption initiated by CRP, but not by IgG. Replacement of the two 
prolines with alanines,  or scrambling the order of the amino acids, resulted in loss of ability 
of peptide 14-26 to inhibit Clq binding and C activation by CRP, indicating a sequence specificity, 
and not a charge specificity alone, as the basis for the inhibitory activity of the peptide. Similar 
investigations with scrambled peptides showed a sequence specificity for the effects of peptide 
76-92 as well. DNA and heparin inhibited binding of CRP trimers to intact Clq, as well as 
to each peptide 14-26 and 76-92, suggesting involvement of these regions in Clq-CLR binding 
reactions generally. Collectively,  these data identify two cationic regions within residues 14-26 
and 76-92 of the Clq A chain CLR as sites through which CRP binds and activates the classical 
C pathway,  and suggest that these residues represent significant regions for Clq CLR binding 
reactions generally. To our knowledge, this represents the first delineation of sites on Clq through 
which binding and activation of the classical C  pathway can occur. 
C 
-reactive protein (CRP) 1, a prototypic acute-phase reac- 
tant and member of the pentraxin family of proteins 
(2, 3), is known to activate the classical pathway of comple- 
ment via  an interaction with Clq (4,  5).  Recently CRP- 
induced C activation was shown to occur via the collagen- 
like region (CLR) of Clq (6, 7), in contrast to IgG and IgM 
which activate C via the globular region (GR) of Clq (8). 
Other substances in addition to CRP which react with the 
Clq CLR include DNA (9-11), fibronectin (12), heparin (13), 
1 Abbreviations used in this tmper: Agg-IgG, heat-aggregated  IgG; CLR, 
coUagen-like  region  ofClq; CR.P, C-reactive  protein;  DTT, dithiothreitol; 
GR, globular region of Clq; TBS, Tris-buffered  saline; and VBS  2+, 
veronal-buffered  saline with CaC12. 
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and bacterial  lipopolysaccharides  (14). DNA also has been 
shown to activate the classical C pathway (15-17). However, 
since DNA reacts with the GR, as well as with the CLR 
(11), CRP is the only substance  to date shown to activate 
C via the CLR. It therefore was of interest to further define 
the CRP-binding site on the Clq CLR, to better understand 
C  activation initiated by CRP, as well as C  activation via 
the CLR generally. 
Preliminary investigations indicated that CRP reacts pref- 
erentially with the Clq A chain, while heat-aggregated IgG 
(Agg-IgG) reacts with the Clq C chain (1). Both reactions 
occurred in reduced SDS-gels, indicating that linear as op- 
posed to conformational determinants were sufficient  for 
binding of CRP as well as IgG (6). CRP bound to both CLR 
and GR, but the latter reactivity was shown to be attributable 
to reactivity with a CLR "tail" regularly present in prepara- 
tions of GR, suggesting reactivity with a sequence near the 
COOH-terminus of the CLR (6). DNA and fibronectin also 
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been presumed to react with a determinant on the CLR tail 
within amino acid residues 81-97 from the NH2 terminus 
(11,  12).  In additional preliminary experiments DNA, but 
not Agg-IgG, inhibited binding of CRP to Clq (1), consis- 
tent with the hypothesis that CRP binds to Clq via CLR 
residues 81-97. Collectively, these results suggested that CRP 
reacts with A chain residues 81-97, and further, that the CLR 
serves  as a general site for Clq binding and C  activation. 
The present study was initiated to localize the CRP-binding 
site on Clq, and to further investigate C  activation via the 
CLR. The results establish that CRP binds preferentially to 
the Clq A chain, but in the area of CLR residues 76-92 rather 
than 81-97, and in the area of CLR residues 14-26 as well. 
DNA and heparin also bind in both of these regions. CRP- 
trimers,  as  well  as  CRP-ligand  complexes,  bind  to  these 
regions, and both regions seem to be involved in the reac- 
tivity of CRP with the C  system. We believe these results 
provide the first delineation of Clq sites through which the 
classical  C  pathway can be activated. 
Materials  and Methods 
Aggregated Human IgG (Agg-lgG).  Human lgG (Gamastan) was 
purchased  from Miles Laboratories (Elkhart,  IN),  and  further 
purified by FPLC Superose 12 preparative column chromatography 
in the presence of 10 mM Tris-buffered saline (TBS). To prepare 
Agg-IgG,  IgG (7.5 mg/ml) was heated at 63~  for 20 min im- 
mediately before use. 
BSA-anti-BSA  Complexes.  BSA was  purchased from Sigma 
Chemical Co. (St. Louis, MO), and rabbit anti-BSA was purchased 
from Calbiochem Corp. (San  Diego, CA). BSA-anti-BSA  complexes 
were prepared by mixing equal volumes of BSA (20/~g/ml)  and 
anti-BSA (10/~g/ml). 
DNA,  Heparin, and  Pkosphorykholine.  Lyophilized double- 
stranded calf thymus DNA, heparin, and phosphorylcholine were 
obtained from Sigma Chemical Co. 
CRP.  CRP, CRP-ttimers, and CRP-protamine mixtures were 
prepared as previously  described (6, 7), and characterized  using anti- 
CRP mAb (18, 19). 
Clq.  Clq was isolated at 4~  from human plasma by modi- 
fication of the method of Tenner et al. (20). Briefly, 5 mM EDTA 
plasma was applied to a Bio-Rex 70 column (Bio-Rad Laborato- 
ties, Richmond, CA), and eluted with a linear (0.08-0.3 M) NaC1 
gradient. The protein peak was pooled and further purified by gel 
filtration on a preparative Superose 12 FPLC column (Pharmacia 
LKB Biotechnology Inc., Piscataway, NJ). The concentration of 
Clq was determined by its absorbance at 280 nm using an extinc- 
tion coefficient (mg/ml) of 0.68 (21). The purity of the final Clq 
preparation  was  >99%,  as  analyzed by SDS-PAGE with  silver 
staining (Bio-Rad Laboratories), under both unreduced and dithio- 
threitol (DTT)-reduced conditions. The purified protein was stored 
at  - 70~ 
Clq Peptides.  Five  authentic  and four modified Clq A chain 
peptides were synthesized by Research Genetics (Huntsville, AL). 
Clq peptide 81-97 (P-G-S-P-G-N-I-K-D-Q-P-R-P-A-F-S-A)  was syn- 
thesized based on the sequence presented in reference 22, and Clq 
peptides 78-92 (K-G-T-K-G-S-P-G-N-I-K-D-Q-P-R)  and 76-92 ([C]- 
G-I-K-G-T-K-G-S-P-G-N-I-K-D-Q-P-R)  were synthesized at a later 
time based on the sequence presented in reference 23. Data pre- 
sented in the latter reference demonstrated  the presence of a ly- 
sine rather than a proline at position 81. Clq peptides 14-26 (A-G- 
R-P-G-R-R-G-R-P-G-L-K) and 4-26 (C-R-A-P-D-G-K-K-G-E-A- 
G-R-P-G-R-R-G-R-P-G-L-K) also were synthesized based on data 
in reference 23. Peptides similar to 76-92,  but with the proline 
at position 84 replaced with alanine (G-I-K-G-T-K-G-S-A-G-N-I- 
K-D-Q-P-R;  76-92/alanine),  or with the amino acids scrambled 
(D-P-I-G-T-G-K-S-G-G-N-I-D-Q-K-P-R; 76-92Acrambled),  and 
peptides similar to 14-26 but with the prolines at positions 17 and 
23  replaced  with  alanine  (A-G-R-A-G-R-R-G-R-A-G-I~K; 
14-26/alanine), or with the amino acids scrambled (K-G-G-A-P- 
R-R-G-G-L-P-R-R;  14-26/scrambled) were synthesized to help 
evaluate the role of sequence and conformation, as well as charge, 
in the activities of the Clq A chain peptides. 
Biotinylation.  Proteins  were biotinylated by dialyzing into 0.1 M 
sodium bicarbonate buffer (pH 9.0), and incubating with N-hy- 
droxysuccinimide-long-chain-biotin (Pierce Chemical Co., Rock- 
ford, IL) at ratios of 8:1 (wt protein: wt biotin) for 4 h at room 
temperature. The mixtures were dialyzed  twice on a magnetic stirrer 
against 4 liters of 10 mM TBS  2§  at 4~  DNA was biotinylated 
using photoactivatable biotin and a slight modification of the pro- 
cedure from Pierce Chemical Co. Briefly, equal amounts of DNA 
and biotin were mixed in the dark and incubated in an ice bath 
for 15 min under long wave (350-370 nm) UV light. Equal amounts 
of 0.1 M Ttis-HCl (pH 9.0) and 1-butanol were added, the sample 
was mixed and centrifuged, and after washing the lower phase once 
with butanol, equal amounts of  4.0 M NaC1 and ethanol were added. 
The mixture was maintained overnight at  -20~  centrifuged, 
and the precipitated DNA was redissolved in 0.1 mM EDTA, pH 
8.0, for use as a concentrated stock solution. 
SDS-PAGE and Western Blots.  SDS-PAGE  was carried out using 
13% polyacrylamide minislab gels (Bio-Rad Laboratories) and the 
buffer system described by Laemmli (24). Intact Clq and the sepa- 
rated Clq chains were transferred to nitrocellulose  membranes using 
the Bio-Rad transbtot system (25). The nitrocellulose paper was 
incubated with  1% BSA for 30 min at room temperature,  and 
washed three times with veronal-buffered saline containing 2 mM 
CaC12 veronal buffered saline with CaC12 (VBS  2+)  and 0.05% 
Tween 20. Biotinylated CRP was added for 30 rain at 37~  fol- 
lowed by washing, and reacted with strepavidin-peroxidase  (Jackson 
Immunoresearch Laboratories, West Grove, PA). Color was devel- 
oped by 4-chloro-l-naphthol  (Bio-Rad Laboratories). 
Solid Phase Binding Assays.  Wells  of microtiter  plates (C. A. 
Greiner and Sohne, Nurtingen, Germany) were coated overnight 
at room temperature with 50 #1 peptide per well (100 #g/ml) and 
air-dried to the plate. After washing, the plates were backcoated 
with BSA (100 #1 of a 1% solution), and incubated at 37~  for 
30 rain. The plates were washed with 0.075 M VBS  2§  and bio- 
tinylated protein was added (37~  30 rain), followed by washing 
and the addition of streptavidin-peroxidase  (Jackson Immunoresearch 
Laboratories). The plates were incubated for another 30 min at 37~ 
washed, and substrate (ABTS in 0.1 M sodium citrate at pH 4.0; 
Bio-Rad Laboratories) was applied. Reactions were developed at 
37~  for 10-30 rain,  and the A414 was read in a Titertek Mul- 
tiskan MC plate reader (Flow Laboratories, Helsinki, Finland). 
Complement Source.  Human serum was obtained from healthy 
blood donors and stored at -70~  until required. C1 and C2 were 
prepared from guinea pig serum as described by Nelson et al. (26). 
C4-deficient guinea pig serum was the kind gift of Dr. Alexander 
P. Osmand (Oak Ridge Laboratories, Knoxville, TN). Guinea pig 
serum diluted in GVB-EDTA was used as the source of terminal 
C  (C3-9) components. 
Total Complement (CHso) and  C4  Consumption Assays.  The 
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Mayer (28). A mixture of 0.1 ml of 1:10 human  serum and 0.1 
ml test material (usually CRP-protamine complexes)  was incubated 
for 30 min at 37~  Twofold  dilutions were prepared, 0.1 ml erythro- 
cytes (E) sensitized with hemolysin (Gibco Laboratories, Chagrin 
Falls, OH;  10  s sensitized cells/ml)  were added and the mixture 
was  incubated  for 30 rain  at  37~  GVB-EDTA (1.0 ml)  was 
added, and after centrifugation,  the OD of the supernatant  was 
measured at 412 nm. C4 hemolytic activity was measured exactly 
as described (29). 
Data Presentation.  Each experiment reported was performed in 
duplicate and repeated two to three times. The error bars represent 
+  1 SD. Representative figures are shown. 
Results 
Preferential Reactivity of CRP with the Clq A  Chain.  To 
test the relative reactivity of CRP with the separate Clq chains, 
Clq  was  reduced  with  DTT,  subjected  to  SDS-PAGE  in 
minislab gels, transferred to nitrocellulose paper, and reacted 
with biotinylated CRP-trimers.  As shown in Fig.  1,  CRP 
bound  preferentially  to  the  Clq  A  chain,  although  lesser 
binding to the B and C chains was seen in some experiments. 
By comparison, biotinylated Agg-IgG bound preferentially, 
although not exclusively,  to the Clq C chain. This reactivity 
confirmed  the previous demonstration  of binding  of CRP 
(and IgG) to linear rather than conformational determinants 
on Clq (6), suggesting that the reactive site should be definable 
by the use of synthetic Clq peptides, and indicated that the 
binding site for CRP was preferentially present on the Clq 
A  chain. 
Reactivity of CRP with Clq A  Chain Peptide 76-92.  Since 
previous  experiments  had  suggested  that  CRP  binds  to 
COOH-terminal CLR residues retained as a "CLR-like tail" 
on GR preparations  (6),  inferred to involve residues 81-97 
on one or more of the Clq chains (11, 12), Clq A chain pep- 
tide 81-97 was synthesized,  and biotinylated CRP-trimers 
were reacted with  the immobilized  synthetic peptide (Fig. 
2 A). However, no binding was observed. A  second Clq A 
chain peptide (78-92) was synthesized incorporating  an ad- 
Figure 1.  Binding  of  CRP-trimers 
to the A chain of Clq. Intact Clq (1 
#g/lane) was reduced  with DTT and 
subjected  to SDS-PAGE  in 13% poly- 
acrylamide minislab gels, transferred 
to nitrocellulose paper, and reacted 
with  20/zg/ml  biotinylated CRP- 
trimers or Agg-Igg. Color  was devel- 
oped  with streptavidin-peroxidase  and 
substrate (4-chloro-l-naphthol). (Lane 
1) Clq chains visualized with silver 
stain, and (lanes 2 and 3) Clq chains 
were reacted with biotinylated Agg- 
IgG and CRP-trimers, respectively. 
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Figure 2.  (A) Reactivity  of CRP-trimers with Ctq A chain peptides 
14-26, 76-92, 78-92, and 81-97, and (B) reactivity of CRP-protamine 
complexes, CRP-trimers and (for  comparison)  Agg-lgG  with Clq A chain 
peptide 76-92. The Clq peptides (1 mg/ml) were diluted to 0.1 mg/ml 
with ELISA  coating buffer  (0.05 M carbonate  buffer, pH 9.6). Microtiter 
plate wells  were  coated  with 50 #I peptide  per well (5 gig/well) overnight 
at room temperature, and air-dried onto the wells. After  backcoating  with 
1% BSA (100/.tl; 37~  30 rain) and washing (0.075 M VBS  2+, bio- 
tinylated CRP-trimers, CRP-protamine  complexes,  or Agg-lgG (50/~g/m] 
containing up to 50/zg protein/ml) were  added (37~  30 rain). Binding 
was detected using streptavidin-peroxidase. 
ditional three NH2-terminal residues,  including lysine at po- 
sition 78, omitting the four COOH-terminal  residues that 
limited solubility of the peptide, and placing a lysine rather 
than a proline in position 81, as recently clarified  (23). This 
immobilized peptide reacted distinctly, but minimally, with 
the CRP-trimers. A third Clq A chain peptide (residues 76-92) 
involving  two  additional  NH2-terminal  residues  and  an 
NH2-terminal cysteine also was prepared,  and this immobi- 
lized  peptide  showed  significant  binding  of CRP-trimers 
(Fig. 2 A). CRP-protamine complexes bound comparably well 
as CRP-trimers  to peptide 76-92,  while Agg-IgG failed to 
bind  to  this  peptide  (Fig.  2 B).  The binding  was not  due 
to the cysteine added  to the  NH2-terminus  because iodoa- 
cetamide treatment of the peptide did not influence the binding 
activity. The binding of CRpotrimers to peptide 76-92 was 
inhibited by preincubation in the fluid phase with either in- 
tact Clq or peptide 76-92 (Fig. 3 B), although peptide 76-92 
reacted less strongly,  supporting  the specificity of the reac- 
tion and indicating  that  the peptide in the fluid phase,  like 
the immobilized peptide, reacts with CRP. Replacement of 
the proline  at position 84 with  alanine,  or scrambling  the 
order of the amino  acids,  resulted in  loss of the  ability of 
the peptide 76-92 to inhibit binding of CRP-trimers to in- 
tact Clq (Fig. 4 B), indicating a sequence specificity,  and not 
a charge specificity alone, as the basis for its reactivity. Nei- 
ther phosphorylcholine, nor EDTA inhibited binding of CRP 
to peptide 76-92. Peptide 76-92 (but not peptides 78-92 or 
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Figure 3.  Inhibition of binding ofbiotinylated  CRP-trimers (0.5 #g/well) 
to wells coated with Clq A chain peptide 14-26 (A; 5 #g/well) by prein- 
cubation of CR.P-trimers (37~  1 h) with increasing amounts (up to 100 
#g/ml) of Clq (&) or peptide 14-26  (Q), but not peptide 76-92 ([--I); 
and to wells coated with peptide 76-92 (B; 5 ~g/well) by preincubation 
with increasing  amounts (up to 100 #g/ml) of Clq (&), peptide 14-26 
(0) and, to a lesser extent, peptide 76-92 ([]). 
81-97) also inhibited binding of CRP-trimers to intact Clq, 
although less strongly than intact Clq (Fig. 4 B), emphasizing 
a role for residues 76-92 in the binding of CKP by Clq, but 
suggesting that a second site might also be involved. 
Reactivity Of CRP with Clq A  Chain Peptide 14-26.  The 
presence  of  two  lysine  groups  at  the  important  NH2- 
terminal of peptide 76-92 suggested that cationic amino acids 
might be involved in CRP binding at the Clq CLK. Since 
the Clq A chain has cationic residues between amino acids 
4-26 not present on the Clq B or C  chains,  Clq A chain 
peptides 14-26 (with arginine at positions 16, 19, 20, and 
22, and lysine at position 26) and 4-26 (with an additional 
arginine at position 5 and lysines at positions 10 and 11) were 
synthesized and tested for reactivity with CRP. CRP-trimers 
(Fig.  2 A) bound strongly to peptide 14-26, as did CKP- 
protamine complexes (data not shown). Since binding to pep- 
tide 4-26 was no greater than binding to peptide 14-26 (data 
not shown), the smaller peptide was used in further studies. 
Binding of CKP-trimers to immobilized peptide 14-26 was 
inhibited, and to comparable degrees, by both fluid phase pep- 
tide 14-26 and Clq (Fig. 3 A), but not by phosphorylcho- 
line or EDTA. Further, peptide 14-26 also inhibited binding 
of CRP-trimers to immobilized peptide 76-92 comparably 
well as Clq and much more effectively than did fluid phase 
peptide 76-92, while peptide 76-92 did not inhibit the binding 
of CRP-trimers  to  peptide  14-26,  indicating preferential 
binding of peptide 14-26 with CRP (Fig. 3 A). Most strik- 
ingly, peptide 14-26 completely inhibited binding of CRP- 
trimers to intact Clq, supporting the concept that this cat- 
ionic region of the Clq A chain is a major site involved in 
binding CRP (Fig. 4 A). Replacement of the prolines at po- 
sitions 17 and 23 with alanines, or scrambling the order of 
the amino acids, resulted in loss of the ability of comparable 
concentrations of peptide 14-26 to inhibit binding of CKP- 
trimers  to  intact  Clq  (Fig.  4  A),  indicating a  sequence 
specificity, and not a charge specificity alone, as the basis for 
its reactivity. 
Effect of Peptides 14-26  and 76-92 upon C Activation by 
CRP.  Peptides 76-92, 78-92, and 81-97 had no effect on 
C consumption initiated by CKP-protamine complexes, but 
peptide 14-26 induced dose-dependent inhibition of the deple- 
tion of C4 (Fig. 5 A) and total C hemolytic activities other- 
wise observed when CKP and protamine are added to dilute 
normal human serum. ~250 #g/ml peptide 14-26 was re- 
quired for 50% inhibition of CRP-induced C4 consumption. 
This is much greater than the ~2 #g/ml peptide 14-26 re- 
quired for 50% inhibition of binding to Clq (Fig. 4 A), and 
probably reflects the lesser amount of Clq (0.5 rather than 
~11/~g/ml) and CRP (0.5 rather than 20 #g/ml), use of 
CRP trimers rather than CRP-ligand complexes, and absence 
of serum proteins, in the Clq binding assay. Replacement 
of the prolines at positions 17 and 23 with alanines, or scram- 
bling the order of the amino adds, resulted in loss of the 
ability of the peptide 14-26 to inhibit C4 consumption by 
CRP-ligand complexes (Fig. 5 B), again indicating a sequence 
specificity, and not a charge specificity alone, as the bases for 
its reactivity.  Peptide 14-26 had no effect on C4 consump- 
tion initiated by Agg-IgG or BSA-anti-BSA immune com- 
plexes, indicating that this peptide specifically inhibits CKP- 
initiated activation (or perhaps activation via the CLR gener- 
ally) of the classical pathway. 
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Figure 4.  Inhibition of binding of CKP trimers to 
intact Clq by Clq A chain peptides 14-26 (A) and 
76-92 (B), but not by peptides with the amino acids 
scrambled,  or with the prolines replaced by alanine. 
Biotinylated CRP-trimers (0.5  #g/ml) were prein- 
cubated with an equal volume of test peptide (up to 
25 #g/ml for peptide 14-26 and 100 #g/ml for pep- 
tide 76-92), or peptides with the amino acids scram- 
bled (14-26/S and 76-92/S, respectively; O) or with 
the  prolines  replaced  with  alanines  (14-26/A  and 
76-92/A, respectively;  [3) at room temperature for 
120 min before addition to immobilized Clq (0.025 
#g/well). Inhibition of binding by comparable amounts 
of intact Clq (A) is shown for comparison. 
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Figure 5.  Inhibition of C4 depletion induced by CRP-protamine com- 
plexes (20/zg/ml) by increasing amounts (up to 500/~g/well) of peptide 
14-26 (@); peptides 76-92 (O) and 78-92 (A) did not influence C con- 
sumption (A). Peptides identical to 14-26, but with the prolines replaced 
by alanine (O), or with the amino acids scrambled  (I-1) did not inhibit 
C4 consumption initiated by CRP (/3). The peptides had no effect upon 
C4 depletion by Agg-IgG or BSA-anti-BSA immune complexes. 
Use of Sites Within A  Chain Residues 14-26 and 76-92for 
Binding of DNA and Heparin.  To test whether DNA and 
heparin, which are known to react with the Clq CLR (9-11, 
13) also bind to a site(s) contained within residues 14-26 and 
76-92, biotinylated DNA and heparin were reacted with the 
several Clq peptides. Like CRP, DNA and heparin both bound 
strongly to peptides 76-92 and 14-26, and weakly to pep- 
tide 78-92, but failed to bind to peptide 81-97. Further, DNA 
and heparin both blocked binding of CRP-trimers (2 #g/well) 
to intact Clq (0.5/~g/well) (Fig. 6). Only 0.6/~g DNA/well 
and 0.5/~g heparin/well were required for 50% inhibition. 
Comparable amounts of DNA and heparin blocked binding 
of CRP-trimers to immobilized peptides 14-26 and 76-92 
as well (data not shown). These data are consistent with the 
hypothesis that Clq A chain residues 76-92 and 14-26 con- 
tain generally available binding sites for substances reactive 
with the Clq CLR. 
Discussion 
Previous experiments had shown that CRP binds to the 
CLR of Clq near its attachment to the GR (6). In the present 
experiments, this binding was shown to occur preferentially 
to the Clq A chain, and by use of appropriate A chain pep- 
tides, at sites within two cationic regions contained within 
residues 14-26 and 76-92. To our knowledge, this represents 
the first delineation of sites on Clq through which binding 
and activation of the classical C pathway can occur. Although 
several residues on IgG (glutamic acid, lysine, and lysine in 
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Figure 6.  Inhibition of binding ofbiotinylated  CR.P-tfimers (2/~g/well) 
to immobilized  Clq (0.5/~g/well) by preincubation with up to 2.5/~g/well 
DNA (0) or heparin (O); preincubation with Agg-IgG ([]) had no effect. 
positions 318, 320, and 322, respectively) have been impli- 
cated in binding to the Clq GR (30), the exact Clq sequence 
involved has not yet been defined. 
It earlier was thought likely that CRP binds to Clq residues 
81-97,  since these residues were thought to be present on 
standard preparations of both CLR and GR. with which CRP 
(6), DNA (11), and fibronectin (12) react. Peptide 81-97 was 
synthesized according to the amino acid sequence published 
by Reid in 1979 (22), but failed to react with CRP. Peptide 
78-92 next was synthesized according to the genomic sequence 
newly reported by Sellar et al.  (23), which defined residue 
81 as lysine rather than proline. This peptide, which also con- 
tained an additional lysine at position 78, bound CRP weakly. 
Peptide 76-92 was prepared with glycine at position 76, isoleu- 
cine at position 77,  and a NH2-terminal cysteine, and this 
peptide bound CRP strongly. These data are consistent with 
the hypothesis that lysines at positions 78 and 81 of the Clq 
A chain are involved in the binding of CRP, with the binding 
enhanced by the presence of an additional free NH2-terminal 
amino acid group on the peptide. The structure and reac- 
tivity of the Clq chains further support this hypothesis: the 
Clq B chain has only one lysine and the C chain lacks lysine 
residues  at the homologous positions. The relatively  poor 
binding of CRP-trimers to peptide 78-92, which contains 
an additional lysine at position 78,  as well as lysine rather 
than proline at position 81, makes it unlikely that peptide 
81-97 failed to bind CRP because of the incorrect placement 
of proline rather than lysine at position 81. 
The inability of peptide 76-92 to completely inhibit CR.P 
binding to Clq (Fig. 4 B), as well as evidence for two heparin- 
binding sites on the Clq-CLR (13), suggested that a second 
binding site for CRP might be present on the Clq A chain. 
The binding of CRP to a cationic region within Clq A chain 
residues 76-92, along with the presence of another even more 
cationic region within residues  14-26 of the Clq A chain 
not present on the B or C chains, suggested that the second 
site might reside in this region, and this proved to be the 
case. CRP bound strongly to peptide 14-26 (which contains 
four arginine and one lysine residues)  and to peptide 4-26 
(which contains an additional arginine and two lysines) as 
well. Comparable binding was observed to both of the latter 
two peptides, suggesting that the CRP-binding site in this 
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tide 14-26 completely inhibited, and peptide 76-92 partially 
inhibited, binding of CRP-trimers to intact immobilized Clq, 
in further support  of the concept  that these two cationic 
regions on the Clq A chain both represent binding sites for 
CRP, with greater binding activity expressed by the region 
within residues 14-26.  Inhibition of CRP-initiated C con- 
sumption by peptide 14-26 further supported this hypoth- 
esis. It also is plausible that peptides 14-26 and 76-92 inhibit 
by reacting with the same region(s) of CRP,  since soluble 
peptide  14-26 was more effective than peptide 76-92 in in- 
hibiting binding of CRP to immobilized peptide 76-92,  as 
well as to itself and intact Clq.  It is not yet clear whether 
the ability ofpeptide 14-26 but not peptide 76-92 to inhibit 
C  activation by CRP,  and the greater effectiveness of this 
peptide in inhibiting the binding of CRP to Clq,  can be 
attributed to the preferential presence of arginine groups, to 
its  greater  total  positive  charge,  or  to  its  conformation. 
Whatever the basis, the present investigations point to a pre- 
dominant importance for a site within residues 14-26 of the 
Clq A chain in C binding and activation by CRP, and sug- 
gest that perhaps this peptide or an appropriate analogue will 
prove to be effective in the modulation of CRP-initiated C 
activation in vivo. Studies with recombinant Clq should lead 
to definitive characterization  of the Clq binding site(s) for 
CRP. 
Previous studies with mAb and intact Clq or Clq-CLR 
fragments, rather than with Clq A chain peptides, indicated 
that a site in the region of residues 76-92 also is important 
to C activation by CRP (1, 6). Six cationic amino acids are 
present within residues 14-26 of the three chains that com- 
prise each Clq subunit and five of these reside on the A chain. 
By contrast,  nine cationic  amino acids are present  within 
residues 76-92 of the three chains that comprise each Clq 
subunit and only four of these reside on the A chain. Perhaps 
maximal binding to the latter region is dependent upon the 
cumulative effect of cationic residues on each of the Clq chains 
and not on the A chain only, and hence would better be seen 
with intact Clq or Clq-CLR than with peptides from any 
single Clq chain. 
Two types of modified peptides were synthesized to test 
whether the reactivity of the cationic peptides 14-26 and 76-92 
was based on sequence specificity, and not attributable  to 
charge specificity alone. Generally, scrambling the order of 
the residues within the peptides, or simply replacing the pro- 
lines with alanine at positions  17 and 23 of peptide  14-26 
or at position 84 of peptide  76-92  to remove the proline- 
glycine bends and change the peptide conformation, resulted 
in loss of the inhibitory activities of both of the peptides. 
This indicated that charge alone was insufficient, and that 
an appropriate amino acid sequence was needed, for the pep- 
tides to be reactive with CRP. 
Heparin and DNA inhibited binding of CRP to both pep- 
tides, suggesting that these two anionic substances also bind 
to sites containing Clq A chain residues 14-26 and 76-92. 
Experiments involving chemical modification suggested that 
bacterial lipopolysaccharide might bind to the Clq B or C 
chain in the region of histidines at positions 44 or 58, respec- 
tively (14). However, it is not yet clear whether lipopolysac- 
charides or other substances that bind to the Clq CLR, in- 
cluding fibronectin  (12), collagen  (31), laminin  (32), and 
fibrinogen (33) also bind in the region of residues 14-26 and 
76-92,  or whether other regions of the CLR are involved 
in binding of CRP, DNA and the other substances as well. 
C activation initiated by CRP which occurs via the CLR, 
like IgG-initiated C activation which occurs via the GR, results 
in consumption of large amounts of classical pathway com- 
ponents C1, C4, C2, and C3, as well as C-dependent opso- 
nization  and cytolysis (2, 3, 34-37).  However, the mecha- 
nism of C1  activation  via  the CLR  nonetheless  may be 
different, e.g., it is yet to be established whether the C1 sub- 
components are used in a similar way. Since many biologi- 
cally significant  agents  including endotoxin,  viruses, and 
rnucopolysaccharides  react directly with Clq (reviewed  in ref- 
erence 38), it will be of interest to further define C binding 
and activation reactions via the two regions of the Clq A 
chain CLR identified in the present report. To our knowl- 
edge, this represents the first delineation of sites on the Clq 
CLR through which binding and activation of the classical 
C  pathway can occur. 
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